Image Place holder

Hung T. Khong, MD


Specialty: Medical Oncology
Program: Breast Oncology

Call 1-888-MOFFITT
(1-888-663-3488)

or call 1-888-MOFFITT
(1-888-663-3488)

Overview

Dr. Khong's clinical interests include breast cancer and cancer immunotherapy.  He specializes in the treatment of breast cancer of all stages.  He is interested in combining treatment methods such as chemotherpy or radiotherapy with immunotherapy and chemotherapy with targeted therapy. Dr. Khong has developed several innovative clinical trials for the neoadjuvant treatment of stages II and II breast cancer, and first-line therapy for metastatic breast cancer.  He brings to Moffitt and innovative clinical trial that is the first in the country to combine endocrine therapy and checkpoint inhibitors in the neoadjuvant treatment of hormone-receptor positive breast cancer.

Education & Training

Board Certification:

  • Medical Oncology

Fellowship:

  • National Cancer Institute - Medical Oncology
  • National Cancer Institute - Surgery Branch

Residency:

  • Baylor College of Medicine - Internal Medicine Program

Medical School:

  • Temple University School of Medicine - MD
Participating Trials

CLINICAL TRIAL 19393
A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone in Patients with High Risk, Node Positive, Early Stage,Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
Condition:
Intervention: Abemaciclib; LY2835219 (Abemaciclib)
Open

CLINICAL TRIAL 18356
A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients who have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy
Condition:
Intervention:
Open

CLINICAL TRIAL 18386
A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy
Condition:
Intervention: Not Applicable
Open

CLINICAL TRIAL 18844
A Phase 2 Study of Cediranib in Combination with Olaparib in Advanced Solid Tumors
Condition:
Intervention: AZD2171 (Cediranib); Cediranib (Recentin); Olaparib (Lynparza)
Open

CLINICAL TRIAL 19105
A Phase 1b Study of Safety and Immune Response to PVX-410 Vaccine Alone and in Combination with an Antibody Targeting the PD-1/PD-L1 Pathway in HLA-A2+ Subjects Who Have Completed Initial Standard Treatment of Stage II or III Triple Negative Breast Cancer (TNBC)
Condition:
Intervention: AMP-514 (Durvalumab); Durvalumab; MEDI4736 (Durvalumab); PVX-410
Open

CLINICAL TRIAL 18621
A Phase 1/2 Study of Talimogene laherparepvec in Combination with Neoadjuvant Chemotherapy in Triple Negative Breast Cancer
Condition:
Intervention: Adriamycin (doxorubicin); Talimogene laherparepvec 10^6 PFU (Talimogene Laherparepvec); Talimogene laherparepvec 10^8 PFU (Talimogene Laherparepvec); Taxol (paclitaxel); cyclophosphamide; cytoxan (cyclophosphamide); doxorubicin; paclitaxel
Open

CLINICAL TRIAL 18936
A Phase I-II Study of Interferon-gamma Plus Weekly Paclitaxel, Trastuzumab and Pertuzumab in Patients with HER-2 Positive Breast Cancer
Condition:
Intervention: Herceptin (Trastuzumab); Pertuzumab; Taxol (paclitaxel); Trastuzumab; interferon gamma (Actimmune); paclitaxel; rhuMAb HER2 (Trastuzumab)
Open

CLINICAL TRIAL 18810
Phase 1b Study To Assess The Safety, Tolerability, and Clinical Activity of Gedatolisib in Combination with Palbociclib and Either Letrozole Or Fulvestrant in Women with Metastatic or Locally Advanced/Recurrent Breast Cancer (Mbc)
Condition:
Intervention: 772256 (Palbociclib); Faslodex (fulvestrant); Femara (Letrozole); Gedatolisib; Letrozole; PF-05212384 (Gedatolisib); Palbociclib; fulvestrant
Open

CLINICAL TRIAL 19340
Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib vs. Placebo in Combination with Capecitabine and Trastuzumab in Patients with Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma (HER2CLIMB)
Condition:
Intervention: Herceptin (Trastuzumab); Not Applicable; Placebo; Trastuzumab; Tucatinib; Xeloda (capecitabine); capecitabine; rhuMAb HER2 (Trastuzumab)
Open

CLINICAL TRIAL 19117
A Multicenter Phase II Study of Vaccines to Prevent Recurrence in Patients with HER-2 Positive Breast Cancer
Condition:
Intervention:
Open

CLINICAL TRIAL 19328
SHERBOC: A Double-blind, Placebo-controlled, Phase 2 trial of Seribantumab Plus Fulvestrant in Postmenopausal Women with Hormone Receptor-positive, Heregulin Positive (HRG+), HER2 Negative Metastatic Breast Cancer Whose Disease Progressed After Prior Systemic Therapy
Condition:
Intervention: Faslodex (fulvestrant); Not Applicable; Placebo; Seribantumab; fulvestrant
Open

CLINICAL TRIAL 16664
A Phase I-II Study of PTX-200 Plus Sequential Weekly Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide in Patients with Metastatic and Locally Advanced Breast Cancer
Condition:
Intervention: Adriamycin (doxorubicin); Taxol (paclitaxel); Triciribine (TCN-PM (0002)); cyclophosphamide; cytoxan (cyclophosphamide); doxorubicin; paclitaxel
Open

CLINICAL TRIAL 19337
A Pilot Study Utilizing a HER2 Directed Dendritic Cell Vaccine During Neoadjuvant Therapy of HER2+ Breast Cancer
Condition:
Intervention: DC1 Vaccine; Herceptin (Trastuzumab); Paraplatin (carboplatin); Pertuzumab; Taxotere (docetaxel); Trastuzumab; carboplatin; docetaxel; rhuMAb HER2 (Trastuzumab)
Open

CLINICAL TRIAL 19455
A Multicenter Phase 2 Study of the Glutaminase Inhibitor CB-839 in Combination with Paclitaxel in Patients with Advanced Triple Negative Breast Cancer (TNBC) Including Patients of African Ancestry and Non-African Ancestry
Condition:
Intervention: CB-839; Taxol (paclitaxel); paclitaxel
Open

CLINICAL TRIAL 19394
An Open-Label, Single-Arm Pilot Study Evaluating The Antitumor Activity And Safety Of Niraparib As Neoadjuvant Treatment In Localized, Her2-Negative, Brca-Mutant Breast Cancer Patients
Condition:
Intervention: Niraparib
Open

CLINICAL TRIAL 19109
A Phase 1/2, Open-label, Multicenter, Dose Escalation and Dose Expansion Study of NKTR-214 and Nivolumab in Patients with Select Locally Advanced or Metastatic Solid Tumor Malignancies
Condition:
Intervention: BMS-936558 (Nivolumab); NKTR-214; Nivolumab
Open

CLINICAL TRIAL 19603
Single Arm, Open Label Phase 1b/2 Study of SGN-LIV1A in Combination with Pembrolizumab for First-Line Treatment of Patients with Unresectable Locally-Advanced or Metastatic Triple-Negative Breast Cancer
Condition:
Intervention: Pembrolizumab (Keytruda); SGN-LIV1A
Open

CLINICAL TRIAL 19480
The Reveal Study: A Phase 1/2, Open-Label, Multicenter, Dose Escalation And Dose Expansion Study Of Nktr-262 In Combination With Nktr-214 And In combination With Nktr-214 Plus Nivolumab In Patients With Locally Advanced Or Metastatic Solid Tumor Malignancies
Condition:
Intervention: BMS-936558 (Nivolumab); NKTR-214; NKTR-262; Nivolumab
Open

If you believe you are eligible for one of these trials or studies, please call
1-888-MOFFITT (1-888-663-3488).

Publications

  • Ma J, Kuzman J, Ray A, Lawson BO, Khong B, Xuan S, Hahn AW, Khong HT. Neutrophil-to-lymphocyte Ratio (NLR) as a predictor for recurrence in patients with stage III melanoma. Sci Rep. 2018 Mar;8(1):4044. Pubmedid: 29511262. Pmcid: PMC5840418.
  • Gardner LJ, Ward M, Andtbacka RHI, Boucher KM, Bowen GM, Bowles TL, Cohen AL, Grossmann K, Hitchcock YJ, Holmen SL, Hyngstrom J, Khong H, McMahon M, Monroe MM, Ross CB, Suneja G, Wada D, Grossman D. Risk factors for development of melanoma brain metastasis and disease progression: a single-center retrospective analysis. Melanoma Res. 2017 Oct;27(5):477-484. Pubmedid: 28800031. Pmcid: PMC5583702.
  • Bowen RC, Little NAB, Harmer JR, Ma J, Mirabelli LG, Roller KD, Breivik AM, Signor E, Miller AB, Khong HT. Neutrophil-to-lymphocyte ratio as prognostic indicator in gastrointestinal cancers: a systematic review and meta-analysis. Oncotarget. 2017 May;8(19):32171-32189. Pubmedid: 28418870. Pmcid: PMC5458276.
  • Lawson BO, Khong HT. Narcoleptic-like Episodes in a Patient Receiving Pegylated Interferon-alpha 2b: A Case Report and Review of Literature. Anticancer Res. 2017 Mar;37(3):1365-1368. Pubmedid: 28314304.
  • Bowen RC, Hahn AW, Butler TW, Khong HT. Complete response to azacitidine priming and nab-paclitaxel in non-Hodgkin lymphoma resistant to biochemotherapy. Mol Clin Oncol. 2017 Jan;6(1):122-124. Pubmedid: 28123744. Pmcid: PMC5245156.
  • Cohen AL, Ray A, Van Brocklin M, Burnett DM, Bowen RC, Dyess DL, Butler TW, Dumlao T, Khong HT. A phase I trial of azacitidine and nanoparticle albumin bound paclitaxel in patients with advanced or metastatic solid tumors. Oncotarget. 2017 Aug;8(32):52413-52419. Pubmedid: 28881739. Pmcid: PMC5581038.
  • Werner TL, Ray A, Lamb JG, VanBrocklin M, Hueftle K, Cohen AL, Beck AC, Buys SS, Dyess DL, Butler TW, Dumlao TL, Neumayer L, Khong HT. A Phase I Study of Neoadjuvant Chemotherapy With Nab-Paclitaxel, Doxorubicin, and Cyclophosphamide in Patients With Stage II to III Breast Cancer. Clin Breast Cancer. 2017 11;17(7):503-509. Pubmedid: 28579139.
  • Ray A, Williams MA, Meek SM, Bowen RC, Grossmann KF, Andtbacka RH, Bowles TL, Hyngstrom JR, Leachman SA, Grossman D, Bowen GM, Holmen SL, VanBrocklin MW, Suneja G, Khong HT. A phase I study of intratumoral ipilimumab and interleukin-2 in patients with advanced melanoma. Oncotarget. 2016 Sep;7(39):64390-64399. Pubmedid: 27391442. Pmcid: PMC5325451.
  • Liu Z, Smith KR, Khong HT, Huang J, Ahn EE, Zhou M, Tan M. miR-125b regulates differentiation and metabolic reprogramming of T cell acute lymphoblastic leukemia by directly targeting A20. Oncotarget. 2016 Nov;7(48):78667-78679. Pubmedid: 27637078. Pmcid: PMC5346668.
  • Cohen AL, Ray A, Van Brocklin M, Burnett DM, Bowen RC, Dyess DL, Butler TW, Dumlao T, Khong HT. A phase I trial of azacitidine and nanoparticle albumin bound paclitaxel in patients with advanced or metastatic solid tumors. Oncotarget. 2016 Dec. Pubmedid: 28039455.
  • Ray A, Khong B, Khong HT. A Case Report of Pneumocystis Jiroveci Pneumonia in a Patient with Metastatic Breast Cancer. Anticancer Res. 2016 Dec;36(12):6673-6676. Pubmedid: 27920001.
  • Duffy KL, Truong A, Bowen GM, Andtbacka RH, Hyngstrom J, Bowles T, Grossmann K, Khong H, Hyde M, Florell SR, Bowen AR, Wada D, Grossman D. Adequacy of 5-mm surgical excision margins for non-lentiginous melanoma in situ. J Am Acad Dermatol. 2014 Oct;71(4):835-838. Pubmedid: 25219711. Pmcid: PMC4167347.
  • Liu Z, Liu H, Desai S, Schmitt DC, Zhou M, Khong HT, Klos KS, McClellan S, Fodstad O, Tan M. miR-125b functions as a key mediator for snail-induced stem cell propagation and chemoresistance. J Biol Chem. 2013 Feb;288(6):4334-4345. Pubmedid: 23255607. Pmcid: PMC3567684.
  • Andtbacka RH, Donaldson MR, Bowles TL, Bowen GM, Grossmann K, Khong H, Grossman D, Anker C, Florell SR, Bowen A, Duffy KL, Leachman SA, Noyes RD. Sentinel lymph node biopsy for melanoma in pregnant women. Ann Surg Oncol. 2013 Feb;20(2):689-696. Pubmedid: 23054111.
  • Howell PM, Liu Z, Khong HT. Demethylating Agents in the Treatment of Cancer. Pharmaceuticals (Basel). 2010 Jul;3(7):2022-2044. Pubmedid: 27713340. Pmcid: PMC4036667.
  • Wang Y, Radfar S, Liu S, Riker AI, Khong HT. Mitf-Mdel, a novel melanocyte/melanoma-specific isoform of microphthalmia-associated transcription factor-M, as a candidate biomarker for melanoma. BMC Med. 2010 Feb;8:14. Pubmedid: 20163701. Pmcid: PMC2839965.
  • Wang Y, Radfar S, Khong HT. Activated CD4+ T cells enhance radiation effect through the cooperation of interferon-gamma and TNF-alpha. BMC Cancer. 2010 Feb;10:60. Pubmedid: 20178622. Pmcid: PMC2843673.
  • Zhao YH, Zhou M, Liu H, Ding Y, Khong HT, Yu D, Fodstad O, Tan M. Upregulation of lactate dehydrogenase A by ErbB2 through heat shock factor 1 promotes breast cancer cell glycolysis and growth. Oncogene. 2009 Oct;28(42):3689-3701. Pubmedid: 19668225.
  • Radfar S, Wang Y, Khong HT. Activated CD4+ T cells dramatically enhance chemotherapeutic tumor responses in vitro and in vivo. J Immunol. 2009 Nov;183(10):6800-6807. Pubmedid: 19846868.
  • Barve M, Bender J, Senzer N, Cunningham C, Greco FA, McCune D, Steis R, Khong H, Richards D, Stephenson J, Ganesa P, Nemunaitis J, Ishioka G, Pappen B, Nemunaitis M, Morse M, Mills B, Maples PB, Sherman J, Nemunaitis JJ. Induction of immune responses and clinical efficacy in a phase II trial of IDM-2101, a 10-epitope cytotoxic T-lymphocyte vaccine, in metastatic non-small-cell lung cancer. J Clin Oncol. 2008 Sep;26(27):4418-4425. Pubmedid: 18802154.
  • Riker AI, Radfar S, Liu S, Wang Y, Khong HT. Immunotherapy of melanoma: a critical review of current concepts and future strategies. Expert Opin Biol Ther. 2007 Mar;7(3):345-358. Pubmedid: 17309326.
  • Zhao Y, Zheng Z, Khong HT, Rosenberg SA, Morgan RA. Transduction of an HLA-DP4-restricted NY-ESO-1-specific TCR into primary human CD4+ lymphocytes. J Immunother. 2006 Jul;29(4):398-406. Pubmedid: 16799335. Pmcid: PMC1510955.
  • Wang QJ, Hanada K, Perry-Lalley D, Bettinotti MP, Karpova T, Khong HT, Yang JC. Generating renal cancer-reactive T cells using dendritic cells (DCs) to present autologous tumor. J Immunother. 2005 Nov;28(6):551-559. Pubmedid: 16224272.
  • Huang J, Khong HT, Dudley ME, El-Gamil M, Li YF, Rosenberg SA, Robbins PF. Survival, persistence, and progressive differentiation of adoptively transferred tumor-reactive T cells associated with tumor regression. J Immunother. 2005 May;28(3):258-267. Pubmedid: 15838383. Pmcid: PMC2174599.
  • Klebanoff CA, Khong HT, Antony PA, Palmer DC, Restifo NP. Sinks, suppressors and antigen presenters: how lymphodepletion enhances T cell-mediated tumor immunotherapy. Trends Immunol. 2005 Feb;26(2):111-117. Pubmedid: 15668127. Pmcid: PMC1388277.
  • Liu G, Akasaki Y, Khong HT, Wheeler CJ, Das A, Black KL, Yu JS. Cytotoxic T cell targeting of TRP-2 sensitizes human malignant glioma to chemotherapy. Oncogene. 2005 Aug;24(33):5226-5234. Pubmedid: 15897911.
  • Zhao Y, Zheng Z, Robbins PF, Khong HT, Rosenberg SA, Morgan RA. Primary human lymphocytes transduced with NY-ESO-1 antigen-specific TCR genes recognize and kill diverse human tumor cell lines. J Immunol. 2005 Apr;174(7):4415-4423. Pubmedid: 15778407. Pmcid: PMC2174604.
  • Khong HT, Yang JC, Topalian SL, Sherry RM, Mavroukakis SA, White DE, Rosenberg SA. Immunization of HLA-A*0201 and/or HLA-DPbeta1*04 patients with metastatic melanoma using epitopes from the NY-ESO-1 antigen. J Immunother. 2004 Nov;27(6):472-477. Pubmedid: 15534491. Pmcid: PMC2227905.
  • Khong HT, Wang QJ, Rosenberg SA. Identification of multiple antigens recognized by tumor-infiltrating lymphocytes from a single patient: tumor escape by antigen loss and loss of MHC expression. J Immunother. 2004 May;27(3):184-190. Pubmedid: 15076135. Pmcid: PMC2275330.
  • Liu G, Khong HT, Wheeler CJ, Yu JS, Black KL, Ying H. Molecular and functional analysis of tyrosinase-related protein (TRP)-2 as a cytotoxic T lymphocyte target in patients with malignant glioma. J Immunother. 2003 Jul;26(4):301-312. Pubmedid: 12843792.
  • Khong HT, Restifo NP. Natural selection of tumor variants in the generation of "tumor escape" phenotypes. Nat Immunol. 2002 Nov;3(11):999-1005. Pubmedid: 12407407. Pmcid: PMC1508168.
  • Khong HT, Rosenberg SA. The Waardenburg syndrome type 4 gene, SOX10, is a novel tumor-associated antigen identified in a patient with a dramatic response to immunotherapy. Cancer Res. 2002 Jun;62(11):3020-3023. Pubmedid: 12036907. Pmcid: PMC2561957.
  • Thurber SE, Khong HT, Kammula US, Rosenberg SA. Identification of endogenous HLA-A2-restricted reactivity against shared melanoma antigens in patients using the quantitative real-time polymerase chain reaction. J Immunother. 2002 Jan;25(1):63-71. Pubmedid: 11924911. Pmcid: PMC2424231.
  • Khong HT, Rosenberg SA. Pre-existing immunity to tyrosinase-related protein (TRP)-2, a new TRP-2 isoform, and the NY-ESO-1 melanoma antigen in a patient with a dramatic response to immunotherapy. J Immunol. 2002 Jan;168(2):951-956. Pubmedid: 11777994. Pmcid: PMC2430890.
  • Khong HT, McCarthy J. Chlorambucil-induced pulmonary disease: a case report and review of the literature. Ann Hematol. 1998 Jul;77(1-2):85-87. Pubmedid: 9760160.